ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Fibroblasts, Synovial"

  • Abstract Number: 1770 • ACR Convergence 2023

    Dual Inhibition of TNF-α and OX40L on Synovial Inflammation and Osteoclastogenesis in Rheumatoid Arthritis

    Hee Sung Kwon1, Mi Hyeon Kim2, Jeoung Yeon Kim2, Seon Uk Kim2, Hae Rim Kang1, Seo Yoon Ban3, Gyong Sik Ha4, Chung Min Lee4, Jeong Seok Lee5 and Eun Young Lee2, 1Interdisciplinary Program in Cancer Biology, Integrated Major in Innovative Medical Science, Seoul National University, Seoul, South Korea, 2Seoul National University College of Medicine, Seoul, South Korea, 3Department of Cancer biology, Graduate School of College of Medicine, Seoul National University, Seoul, South Korea, 4Research institute, IMBiologics Corp, Suwon, South Korea, 5Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Seoul, South Korea

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease that leads to progressive cartilage and bone destruction. TNF superfamily member OX40 ligand (OX40L; CD252) is…
  • Abstract Number: 0798 • ACR Convergence 2023

    A Novel 3D Model of Rheumatoid Arthritis Synovial Tissue Incorporating Fibroblasts, Endothelial Cells and Macrophages

    Eva Philippon1, Lisanne van Rooijen1, Jan Piet van Hamburg1, Fatemeh Khodadust1, Conny Van der Laken2 and Sander Tas3, 1Amsterdam University Medical Centers, Amsterdam, Netherlands, 2Amsterdam UMC - location VUMC, Amsterdam, Netherlands, 3Amsterdam UMC, locatie AMC, Utrecht, Netherlands

    Background/Purpose: Rheumatoid Arthritis (RA) is a progressive and systemic autoimmune disorder associated with chronic and destructive inflammation of the joints. The hallmarks of RA are…
  • Abstract Number: 1773 • ACR Convergence 2023

    Integrated Analysis of Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS) Transcriptome and Chromatin Accessibility Identifies Mechanisms Associated with Location-specific Disease Severity

    Eunice Choi1, Camilla R. L. Machado2, David Boyle1, Wei Wang1 and Gary Firestein2, 1University of California San Diego, La Jolla, CA, 2University of California San Diego, San Diego, CA

    Background/Purpose: Mechanisms responsible for the distribution and severity of joint involvement in RA are not known. To explore whether site-specific FLS biology might contribute to…
  • Abstract Number: 0802 • ACR Convergence 2023

    Targeting Fibroblasts in Inflammatory Disease Using Engineered T Cells

    Samuel Kemble1, Christopher Mahony2, Charlotte Smith2, Joel Rurik3, Haig Aghajanian3, Jonathan Epstein3, Mark Coles4 and Adam Croft2, 1University Birmingham, Rugeley, United Kingdom, 2University of Birmingham, Birmingham, United Kingdom, 3University of Pennsylvania, Philadelphia, PA, 4University of Oxford, Oxford, United Kingdom

    Background/Purpose: Fibroblast activation protein alpha (FAPa) expressing fibroblasts orchestrate tissue inflammation and damage in rheumatoid arthritis (RA) as well as tissue immunity in primary Sjögren's…
  • Abstract Number: 1775 • ACR Convergence 2023

    The Peptidyl Arginine Deiminase Inhibitor BB-CLA Decreases the Inflammatory and Fibrotic Responses in Macrophages and Rheumatoid Arthritis Synovial Fibroblasts Exposed to Fibrinogen Modified with Malondialdehyde-Acetaldehyde Adduct and Citrulline

    Jack Mordeson1, Nozima Aripova1, Michael Duryee1, James O'Dell1, Bryant England1, Daniel Anderson1, Ted R Mikuls2 and Geoffrey Thiele1, 1University of Nebraska Medical Center, Omaha, NE, 2Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Peptide citrullination and adduction with malondialdehyde-acetaldehyde adduct (MAA) are post-translational modifications involved in the pathogenesis of rheumatoid arthritis (RA). Anti-cyclic-citrullinated peptide antibodies are >90%…
  • Abstract Number: 081 • 2023 Pediatric Rheumatology Symposium

    Predicting Extension in Juvenile Idiopathic Arthritis

    Megan Simonds1, Kathleen Sullivan2 and AnneMarie Brescia1, 1Nemours Children's Health, Wilmington, DE, 2Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood and carries a risk of permanent joint damage and disability [1]. In…
  • Abstract Number: 0579 • ACR Convergence 2022

    Characterization of Terminal Uridyl Transferase Function in Response to Tumor Necrosis Factor-α in Rheumatoid Arthritis Synovial Fibroblasts

    Anil Singh, Farheen Sultan Shaikh and Salahuddin Ahmed, Washington State university, Spokane, WA

    Background/Purpose: Terminal Uridyl Transferase (TUT) genes TUT4 and TUT7 mediate uridylation of mRNA and microRNAs to maintain cellular homeostasis via RNA turnover. Changes in the…
  • Abstract Number: 1148 • ACR Convergence 2022

    GWAS Identified New Genes in Synovial Fibroblasts Linked to Early Remission in RA

    Marc Maurits1, lydia Abasolo Alcazar2, Erik van den Akker3, Johan Askling4, Anne Barton5, Stephan Blüml6, Stephan Böhringer7, Andrew Cope8, Paul Emery9, Stephen Eyre5, Priya Gaddi5, Isidoro Gonzalez10, Carl Goodyear11, Annette van der Helm-van Mil12, Xinli Hu13, Tom Huizinga3, John D Isaacs14, Scott Jelinsky13, Martina Johannesson4, Samantha Jurado Zapata3, Changlin Ke3, Lars Klareskog4, Dennis Lendrem15, Myles Lewis16, Mingdong Liu3, Paul Martin17, Iain B McInnes18, Raphael Micheroli19, Ann Morgan20, Fraser Morton11, Najib Naamane15, Gisela Orozco5, Caroline Ospelt21, Leonid Padyukov4, Caron Paterson11, Darren Plant5, Duncan Porter22, Arthur Pratt23, Soumya Raychaudhuri24, Louise Reynard15, Luis Rodriguez-Rodriguez25, Daniela Sieghart26, Paul Studenic6, John Taylor27, René Toes3, Marloes Verstappen3, Suzanne Verstappen5, Helga Westerlind4, Aaron Winkler13 and Rachel Knevel3, 1LUMC, Leiden, Netherlands, 2IDISSC Hospital Clinico San Carlos, Madrid, Spain, 3Leiden University Medical Center, Leiden, Netherlands, 4Karolinska Institutet, Stockholm, Sweden, 5The University of Manchester, Manchester, United Kingdom, 6Medical University of Vienna, Vienna, Austria, 7Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Leiden, Netherlands, 8King's College London, Surrey, United Kingdom, 9Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 10Hospital Universitario de La Princesa, Madrid, Spain, 11University of Glasgow, Glasgow, Scotland, United Kingdom, 12Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands, 13Pfizer Inc., Cambridge, MA, 14Institute for Translational and Clinical Research, Newcastle University and Musculoskeletal Unit, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, United Kingdom, 15Newcastle University, Newcastle, United Kingdom, 16Queen Mary University of London, London, United Kingdom, 17The University of Manchester, Oberhaching, Germany, 18Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, 19University Hospital Zurich, Department of Rheumatology, Zürich, Switzerland, 20University of Leeds, Leeds, United Kingdom, 21Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 22Gartnavel General Hospital, Bearsden, United Kingdom, 23Newcastle University, Newcastle upon Tyne, United Kingdom, 24Brigham and Women's Hospital, Boston, MA, 25Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain, 26Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, 27University of Leeds, Euclid, OH

    Background/Purpose: In order to understand the genetic factors that lead to early remission in RA, we performed a GWAS to uncover important biological pathways.Methods: We…
  • Abstract Number: 0590 • ACR Convergence 2022

    Molecular Profiling of Normal Human Synovium Reveals Striking Impact of Adipocytes and Homeostatic Cortisol Signaling

    Heather Faust1, Tan-Yun Cheng1, Ilya Korsunsky1, Gerald FM Watts1, David Moody1 and Michael Brenner2, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: The synovium encapsulates joints and contains fibroblasts which proliferate, become invasive, and drive disease progression in rheumatoid arthritis (RA) and osteoarthritis (OA). There is…
  • Abstract Number: 1235 • ACR Convergence 2022

    Fibroblast Activation in Psoriasis Patients Assessed by 68Ga-FAPI-04 PET-CT Is Associated with Progression to Psoriatic Arthritis

    Filippo Fagni1, David Simon2, Arnd Kleyer2, Koray Tascilar2, Jule Taubmann3, Sara Bayat1, Ioanna Minopoulou3, Melek Yalcin Mutlu3, Armin Atzinger4, Torsten Kuwert4, Georg Schett5 and Chrstian Schmidkonz4, 1University Hospital Erlangen; Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, 2Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 3University Hospital Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, 4Friedrich-Alexander University (FAU) Erlangen-Nuremberg, Erlangen, Germany, 5Universitätsklinikum Erlangen, Erlangen, Germany

    Background/Purpose: Prevalence of subclinical inflammatory lesions is high in patients with cutaneous psoriasis and constitutes a -risk constellation for the development of psoriatic arthritis (PsA)1.…
  • Abstract Number: 0594 • ACR Convergence 2022

    Identification of Peptidylglycine Alpha-Amidating Monooxygenase as a Regulator of Tissue Damage Mediated by Rheumatoid Arthritis Synovial Fibroblasts

    Kevin Sheridan1, Emma Dorris1, Christopher Buckley2 and Anthony Wilson1, 1University College Dublin, Dublin, Ireland, 2University of Oxford, Oxford, United Kingdom

    Background/Purpose: The minor C allele variant of rs26232 SNP, located within the first intron of the Macrophage Immunometabolism regulator (MACIR) gene, is associated with both…
  • Abstract Number: 1681 • ACR Convergence 2022

    Supernatants from Activated Macrophages Contain Citrullinated Vimentin and Induce Extracellular Matrix Deposition from Fibroblasts

    nozima Aripova1, Michael Duryee1, Eric Daubach1, carlos hunter1, Bryant England1, James O'Dell1, Ted Mikuls2 and Geoffrey Thiele1, 1University of Nebraska Medical Center, Omaha, NE, 2Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Studies have shown that activated macrophages secrete several factors that promote human fibroblast-like synoviocyte (HFLS) activation, resulting in an invasive phenotype, that contributes to…
  • Abstract Number: 0597 • ACR Convergence 2022

    TNF-α Utilizes the TWEAK/Fn-14 Axis in Human Rheumatoid Arthritis Synovial Fibroblasts

    Farheen Sultan Shaikh, Anil Singh, Paul Panipinto and Salahuddin Ahmed, Washington State University, Spokane, WA

    Background/Purpose: TNF-α is a proinflammatory cytokine in rheumatoid arthritis that exerts effect through specific receptors TNFR1/2. Though it is a primary therapeutic target, there exist…
  • Abstract Number: 1686 • ACR Convergence 2022

    Post-translational Modification of Matrix-gla Protein with Malondialdehyde-Acetaldehyde Alters Cellular Responses by Human Fibroblasts

    Austin Ragland1, Michael Duryee1, nozima Aripova1, Spencer Jones1, Ted Mikuls2 and Geoffrey Thiele1, 1University of Nebraska Medical Center, Omaha, NE, 2Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Post-translational modifications with malondialdehyde-acetaldehyde (MAA) alter protein structure and function, inducing pro-inflammatory and pro-fibrotic responses characteristic of rheumatoid arthritis (RA). Matrix-gla protein (MGP) chelates…
  • Abstract Number: 0600 • ACR Convergence 2022

    Correlates Between Rheumatoid Arthritis Clinical Factors and Synovial Cell Phenotypes: Data from the Accelerated Medicines Partnership

    Dana Weisenfeld1, Fan Zhang2, Laura Donlin3, Anna Jonsson1, William Apruzzese1, Debbie Campbell4, Ellen Gravallese5, Larry Moreland6, Susan Goodman3, Michael Brenner5, Soumya Raychaudhuri1, Andrew Filer7, Jennifer Anolik8, Vivian Bykerk3 and Katherine Liao1, 1Brigham and Women's Hospital, Boston, MA, 2University of Colorado, Aurora, CO, 3Hospital for Special Surgery, New York, NY, 4University of Rochester, Rochester, 5Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 6University of Colorado, Denver, CO, 7University of Birmingham, Birmingham, United Kingdom, 8University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Prior studies have characterized the diverse cell types in the RA synovium through a multi-center consortium incorporating RNA-seq data. Due to the novelty of…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology